American Gastroenterological Association Issues Urgent Guidelines To Combat Rising Liver Cancer Deaths Through Targeted Cirrhosis Prevention

New AGA update identifies cirrhosis prevention as the best way to stop liver cancer. Learn about MASLD, ALD, and the new precision tools for HCC screening.

By: AXL Media

Published: Apr 18, 2026, 10:36 AM EDT

Source: Information for this report was sourced from EurekAlert!

The Growing Global Burden Of Hepatocellular Carcinoma

Hepatocellular carcinoma, or HCC, has solidified its position as the primary cause of cancer-related mortality among patients suffering from cirrhosis and currently stands as the third leading cause of cancer deaths on a global scale. According to a new clinical practice update from the American Gastroenterological Association, the medical community must pivot toward aggressive prevention and early-detection strategies to reverse these trends. While curative treatments exist, their success is entirely dependent on identifying the malignancy at an early stage, a milestone that is currently only met in 30% to 40% of diagnosed cases.

A Shifting Epidemiological Landscape In Liver Disease

The drivers of liver cancer are undergoing a significant transformation, moving away from a historical focus on viral infections toward metabolic and lifestyle-related factors. The AGA reports that metabolic dysfunction associated steatotic liver disease, known as MASLD, and alcohol-related liver disease are now the most rapidly expanding causes of HCC. This shift is dramatically increasing the pool of patients who require regular monitoring, placing a renewed strain on existing clinical infrastructure and highlighting the need for more accessible surveillance methods across a broader demographic.

Eight Best Practice Pillars For Clinical Intervention

To guide physicians through this evolving landscape, the AGA has outlined eight specific best-practice advice statements centered on risk stratification and surveillance. The update emphasizes that reducing liver cancer mortality begins with the effective management of underlying conditions before they progress to cirrhosis. This comprehensive approach includes maintaining high vaccination rates for hepatitis B, providing robust treatment for hepatitis C, and implementing early interventions for patients struggling with alcohol use disorder or metabolic dysfunction.